Safety and Feasibility of Radioembolization Using Ho-166 in Patients With Unresectable Hepatocellular Carcinoma

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 15, 2020

Primary Completion Date

June 10, 2022

Study Completion Date

December 10, 2022

Conditions
Hepatocellular Carcinoma
Interventions
RADIATION

Radioembolization using Holmium-166

This technic consists of the intra-arterial infusion of smaller beads that are loaded with a radioactive isotope (yttrium-90), and it relies on the beta radiation emitted by the isotope to induce tumor necrosis, with a minor contribution from microembolization and without risk of ischemia of the remaining liver.

Trial Locations (1)

1070

Hôpital Universitaire Erasme, ULB, Brussels

All Listed Sponsors
collaborator

Terumo Europe N.V.

INDUSTRY

lead

Erasme University Hospital

OTHER

NCT05643391 - Safety and Feasibility of Radioembolization Using Ho-166 in Patients With Unresectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter